FIND YOUR CONSULTANT
JOIN OUR COMMUNITY
FIND YOUR CONSULTANT
JOIN OUR COMMUNITY

Industries > 

Life Sciences > Generics & Biosimilars Practice

Generics & Biosimilars Practice

Umbrex connects companies in the generics & biosimilars to independent consultants with deep experience in the industry.

Over 90% of our Generics & Biosimilars Practice consultants are alums of McKinsey, Bain, or BCG.

Finding the right consultant should be this easy.

1

Tell us about your project

2

Interview candidates

(We’ll provide bios within 48 hours on average)

3

Select your consultant and start work!

Find a consultant in our Generics & Biosimilars Practice

Prefer email? Write to [email protected]

Client Segments Umbrex Serves

  • Global integrated small‑molecule generics manufacturers: Diversified, integrated groups across oral solids, injectables, and API; drive portfolio renewal, cost leadership, supply reliability, quality, and tender win-rates.
  • Regional branded generics champions: Emerging-market generics companies with branded portfolios and field forces; optimize pricing, distributor management, pharmacy activation, government tenders, PV, and medico-marketing.
  • Complex-dosage generics specialists: Players focused on sterile injectables, inhalation, ophthalmic, transdermal, and drug–device generics; scale R&D/CMC, tech transfers, regulatory pathways, capacity, and lifecycle defense.
  • Pure-play biosimilar developers and commercial platforms: Manufacturers developing, licensing, and marketing biosimilars; strengthen evidence, interchangeability strategies, payer access, tenders, manufacturing economics, and launch excellence globally.
  • Authorized generics and private‑label marketers: Labelers partnering with innovators or ANDA owners; improve channel strategy, pricing, contracting, supply assurance, and retailer-brand architecture.

Selected Capabilities of our Generics & Biosimilars Practice

Strategy & Corporate Development

  • Corporate And Growth Strategy: Define ambition, therapeutic focus, and organic/inorganic growth vectors; align to patent‑cliff opportunities; deliver revenue mix shift, margin expansion, and shareholder value.
  • Portfolio Strategy And Capital Allocation: Prioritize ANDA and biosimilar 351(k) assets using risk‑adjusted NPV and probability of technical/regulatory success; optimize pipeline balance and investment cadence to maximize value.
  • Market Entry And Geographic Expansion Strategy: Assess U.S., EU, and emerging markets, tender regimes, reference pricing, and interchangeability designation; set launch sequencing and localization to accelerate share and profitability.
  • M&A, Licensing, And Partnerships: Screen targets for ANDA assets, biosimilar pipelines, and contract development and manufacturing organizations (CDMOs); structure licensing, joint ventures, and tech transfers to accelerate growth.
  • Vertical Integration And Footprint Strategy: Determine make‑versus‑buy for active pharmaceutical ingredients (API) and finished dose, nearshoring, and capacity; reduce cost‑to‑serve, supply risk, and improve tender competitiveness.

Operations

  • Manufacturing Excellence And OEE Uplift: Deploy lean and total productive maintenance; cut changeovers; raise equipment effectiveness and throughput; reduce cost per batch across oral solids, sterile injectables, and biologics.
  • Technology Transfer And Process Scale-Up: Standardize transfers from R&D/licensors; define control strategy and campaign design; plan process performance qualification (PPQ); achieve right-first-time batches and faster biosimilar and generic time-to-launch.
  • Aseptic Fill-Finish Optimization: Improve sterile operations—line setup, barriers, and interventions; strengthen environmental controls; increase media fill success, line speed, and visual inspection yield; cut rejects and operator touches.
  • Cost Of Goods Reduction And Yield Improvement: Redesign API synthesis and oral solid processes; optimize crystallization, solvent recovery, and granulation; lift yields and batch size; deliver sustained cost of goods sold reduction.
  • Plant Throughput And Cycle-Time Optimization: Debottleneck equipment trains; optimize campaign sequencing and changeovers using Single-Minute Exchange of Die (SMED); raise throughput and schedule adherence; cut manufacturing lead time.

Supply Chain

  • End-To-End Supply Chain Strategy And Network Design: Design API-to-finished-dose network, dual sourcing, nearshoring, decoupling points, and postponement; reduce cost-to-serve, improve service, and mitigate supply and geopolitical risk.
  • Integrated Business Planning Enablement: Stand up Integrated Business Planning (IBP) and Sales and Operations Planning (S&OP); incorporate tenders, price erosion, and constraints; improve forecast accuracy, service levels, and EBITDA.
  • Tender Forecasting And Allocation Planning: Build bid-to-win volumes, probability-weighted demand, and supply commitments; optimize award participation, penalty exposure, and plant allocation; raise win rate and on-time-in-full (OTIF).
  • Inventory Optimization And Shelf-Life Management: Model safety stock across active pharmaceutical ingredients (API), intermediates, and finished product with shelf-life and cold chain constraints; cut expiry, obsolescence, backorders; release working capital.
  • Distribution And 3PL Strategy For Biosimilars: Design channel mix and temperature-controlled logistics; select and contract third-party logistics (3PL); improve Good Distribution Practice (GDP) compliance, cost-to-serve, and service for hospital, tender customers.

Procurement & Strategic Sourcing

  • Category Strategy And Sourcing Wave Deployment: Develop category strategies for API, intermediates, excipients, packaging, single-use; run RFPs and e-auctions; standardize specifications; deliver hard-dollar savings and supply assurance.
  • API And Intermediate Contracting And Indexation: Negotiate long-term agreements with dual sourcing, volume tiers, price indexation for solvents and energy, minimum order quantities (MOQ), lead-time; reduce COGS and volatility risk.
  • Biologics Inputs Procurement Optimization: Source and qualify media, resins, filters, chromatography columns, single-use systems; negotiate framework and consignment; cut lead times and cost; mitigate allocation and quality risk.
  • Contract Manufacturing And External Partner Sourcing: Assess and select contract development and manufacturing organizations (CDMOs); run RFPs; negotiate tech transfer, quality agreements, SLAs, pricing; secure capacity, compliance, and total cost.
  • Supplier Risk And Relationship Management: Stand up supplier risk scoring, monitoring, mitigation; implement supplier development, quarterly business reviews (QBRs), performance scorecards; ensure GxP compliance, continuity, improved on-time-in-full.

Product

  • Target Product Profile And Differentiation Strategy: Define target product profiles for abbreviated new drug application (ANDA) and biosimilar assets; prioritize 505(b)(2) opportunities; codify features and presentations to win tenders.
  • Biosimilar Device And Presentation Strategy: Select auto-injector/prefilled syringe platforms, needle gauges, volumes; plan human factors and training needs; enhance usability, adherence, and payer/provider preference.
  • Lifecycle Management And Line Extension Roadmap: Sequence strengths, pack sizes, presentations, and shelf-life extensions; build business cases; sustain revenue, margin, and tender eligibility.
  • SKU And Packaging Optimization: Rationalize stock keeping units (SKUs); standardize components and artwork; optimize packaging configuration and cold chain; reduce cost of goods sold (COGS), obsolescence, improve tender competitiveness.
  • Global Product Requirements And Market Fit: Translate market, channel, and tender requirements into product requirements; tailor presentations by geography; maximize access, service levels, and profitability.

Organization

  • Operating Model And Organizational Design: Design generics and biosimilars operating model across global and regional levels; set spans, layers, and RACI; align interfaces across development, tech transfer, manufacturing, and commercial.
  • Governance And Decision Rights Redesign: Establish stage-gate governance for abbreviated new drug application (ANDA) and 351(k) biosimilar programs; codify decision rights and escalation; accelerate approvals and reduce cross-functional rework.
  • Global Business Services And Shared Services: Stand up Global Business Services for procurement, finance, master data, and analytics; define service catalogs, service levels, and chargebacks; reduce cost-to-serve and improve scalability.
  • Talent Strategy And Capability Building: Build talent strategy for biologics operations, regulatory, device, and tender management; develop academies and career paths; improve retention, skill depth, and leadership bench.
  • Performance Management And Incentive Architecture: Design KPI hierarchy and incentives aligned to launch timeliness, cost of goods, on-time-in-full, and tender win rate; implement goal cascades and reviews to drive accountability.

Pricing

  • Launch Pricing And Market Access Strategy: Set launch WAC and European list prices, ASP strategy and J-code timelines; model competitor entry and reference pricing; maximize adoption, share, and margin.
  • Tender Pricing And Bid Optimization: Build bid ladders, price corridors, and walk-away points by lot and country; optimize volumes, penalties, and allocation; increase win rate and profitable awards.
  • Gross To Net And Contract Profitability: Design rebate, chargeback, and admin fee structures with wholesalers, PBMs, and GPOs; optimize 340B and Medicaid Best Price exposure; improve net price, margin, and predictability.
  • Price Erosion And Competitive Intelligence: Monitor competitor launch timing, authorized generics, and tender resets; deploy dynamic pricing guardrails and playbooks; slow price erosion and protect contribution margin.
  • Channel And Trade Pricing Strategy: Optimize WAC discounts, wholesaler fees, chargeback tiers, and returns policies across retail, hospital, and specialty channels; reduce price leakage and improve net revenue realization.

Sales

  • Key Account Management And Coverage Model: Design KAM model for wholesalers, chains, GPOs, IDNs; segment portfolios; build account plans, decision maps, and cadences; grow share of wallet and retention.
  • Tender Sales Excellence And Bid Execution: Stand up tender pursuit office, calendars, content libraries, and proposal automation; enforce bid governance; raise win rate, on-time submissions, and post-award onboarding quality.
  • Biosimilar Pull-Through And Field Force Design: Design biosimilar field force, territories, and call plans; enable P&T and pathway engagement; drive pull-through from access wins to adoption, conversions, and repeat orders.
  • Trade Partner Joint Business Planning: Build joint business planning with wholesalers, retail chains, and specialty; align inventory targets, service levels, launch plans; secure preferred status, shelf position, and availability.
  • CRM And Sales Operations Enablement: Implement CRM and sales operations dashboards, opportunity scoring, and playbooks; integrate contract status and supply; improve forecast accuracy, hit rate, and cycle time.

Finance

  • Financial Planning And Analysis Transformation: Stand up driver-based financial planning and analysis (FP&A) forecasting for price erosion, tenders, launches; integrate standard cost and margin bridge; improve predictability and EBITDA visibility.
  • Product, Customer, And Contract Profitability: Build gross-to-net (GTN) waterfall by SKU, customer, and contract; allocate chargebacks, rebates, admin fees; identify unprofitable business; inform bid/no-bid and renegotiation.
  • Gross-To-Net Governance And Accrual Optimization: Design gross-to-net (GTN) forecasting, accruals, true-ups, and reserve policies; model 340B, Medicaid Best Price, and chargeback exposure; reduce earnings surprises and revenue leakage.
  • Working Capital And Deductions Optimization: Redesign order-to-cash, credit, collections; resolve deduction root causes; optimize terms and inventory financing; cut days sales outstanding (DSO) and unlock cash without harming service.
  • Treasury, Foreign Exchange, And Commodity Hedging Strategy: Define foreign exchange (FX) risk appetite and hedging for USD/EUR/INR/CNY; implement commodity index hedges for solvents and energy; optimize liquidity, covenants, and cost of capital.

AI, Data & Analytics

  • Data Platform Modernization And Integration: Build compliant lakehouse integrating ERP, manufacturing execution, lab information, electronic batch records, GTN, and tender data; deliver semantic layer, APIs enabling generics and biosimilars analytics.
  • Tender Intelligence And Price Erosion Analytics: Aggregate global tender data, normalize comparators, model bid-to-win price and erosion; optimize participation, lots, allocations for generics and biosimilars margin.
  • Demand Forecasting And Supply Sensing Models: Build machine learning demand signals from tenders, orders, epidemiology, competitor events; combine with inventory and capacity; improve forecast accuracy, OTIF, and backorder prevention.
  • Manufacturing And Quality Advanced Analytics: Analyze batch records, process historians, and process analytical technology to predict deviations, yield loss, and sterility failures; enable multivariate SPC, anomaly detection, and right-first-time improvements.
  • Data Governance And MLOps Enablement: Establish data stewardship, lineage, metadata, and role-based access; implement compliant model lifecycle, validation, and monitoring; accelerate deployment of AI products under GxP and CSV expectations.

Transformation

  • Enterprise Performance Transformation And EBITDA Uplift: Lead enterprise transformation for generics and biosimilars; deliver rapid diagnostics, value levers, and execution sprints; achieve EBITDA uplift, cash acceleration, and sustainable margin expansion.
  • Transformation Office And Value Capture: Stand up Transformation Office and value capture governance; define workstreams, milestones, owners, and benefits tracking; ensure synergy realization, risk mitigation, and disciplined execution cadence.
  • Zero Based Cost And SG&A Reset: Deploy zero-based budgeting and design-to-value; reset selling, general, and administrative (SG&A), support functions, and indirect spend; capture structural cost reductions without compromising compliance or growth.
  • Post Merger Integration And Carve Out Execution: Execute integrations and carve-outs for generics and biosimilars; integrate portfolios, sites, quality systems, and IT; deliver synergies, exit transition services, and avoid supply disruption.
  • Change Management And Capability Uplift: Create change story, stakeholder mapping, communications, and training academies; build leader standard work; track adoption metrics; sustain outcomes from transformation initiatives.

Sustainability

  • Net Zero Roadmap And Decarbonization Program: Baseline Scope 1/2/3 emissions; set Science Based Targets initiative pathway; build marginal abatement cost curve; prioritize efficiency, electrification, renewable power purchase agreements (PPAs); govern delivery.
  • Energy And Cleanroom Decarbonization: Optimize HVAC setpoints and pressure cascades; deploy heat recovery, variable frequency drives (VFDs), chiller upgrades, and ISO 50001; cut energy intensity and carbon per batch.
  • Solvent Recovery And Green Chemistry Redesign: Redesign API synthesis routes and batch recipes; increase solvent recovery and reuse; switch lower‑impact solvents; reduce volatile organic compounds (VOCs), hazardous waste, cost, and CO2e.
  • Sustainable Supply Chain And Scope 3 Reduction: Quantify Category 1 and 4 emissions; engage suppliers with scorecards and joint abatement; optimize logistics mode, load, and cold chain; deliver verified value chain decarbonization.
  • ESG Reporting And Disclosure Enablement: Build ESG data model and controls; produce CSRD, ISSB climate, and Task Force on Climate-related Financial Disclosures reports; improve CDP and EcoVadis scores.

Compliance

  • Ethics And Compliance Program Design: Establish governance, code, policies, training, and controls tailored to generics and biosimilars; strengthen oversight, culture, and audit readiness across global operations.
  • Anti Bribery And Third Party Risk Management: Design anti-bribery and anti-corruption controls under FCPA and UK Bribery Act; risk-rank distributors and agents; implement due diligence, contract clauses, monitoring; reduce enforcement risk.
  • Tender And Antitrust Compliance: Build tender governance, antitrust guardrails, information-sharing protocols, and bid review committees; enforce documentation and firewalls; prevent collusion risk and ensure compliant public procurement participation.
  • Government Price Reporting And Transparency Compliance: Design controls for AMP, Best Price, 340B, and ASP calculations; align gross-to-net data and audit trails; ensure Sunshine Act and EFPIA transparency accuracy and deadlines.
  • DSCSA Serialization And Traceability Compliance: Stand up DSCSA-compliant processes, EPCIS data exchange, and verification; coordinate with contract manufacturers and distributors; achieve interoperable track-and-trace compliance and timely suspect product investigations.

Program & Portfolio Management

  • Portfolio PMO And Governance: Establish stage-gate governance for ANDA and 351(k) biosimilar programs from development through process performance qualification (PPQ) and launch; improve on-time submissions, first-time-right batches, and time-to-market.
  • Cross-Functional Launch Readiness Management: Run integrated launch plans across manufacturing, quality, regulatory, supply chain, pricing, sales; execute cutover rehearsals and war rooms; hit launch dates, service levels, revenue ramp.
  • Resource And Capacity Portfolio Planning: Balance scarce analytical, formulation, bioequivalence, engineering, and fill-finish capacity; scenario plan and prioritize; lift throughput, shorten cycle time, and increase portfolio on-time-in-full.
  • CDMO And Alliance Program Management: Set partner governance, milestones, and quality/commercial workplans with contract development and manufacturing organizations; track tech transfer and PPQ; reduce delays, deviations, and cost overruns.
  • Portfolio Reporting And Benefits Tracking: Build portfolio dashboards, earned value, and risk burndown; align to business case and net present value; increase transparency, earlier course corrections, and realization of benefits.

Information Technology

  • ERP Transformation And S/4HANA Template: Design pharma ERP blueprint (SAP S/4HANA) with batch costing, gross-to-net, tender, and serialization integration; run fit-to-standard and rollout; improve close speed, traceability, and control.
  • MES And Electronic Batch Record Deployment: Select and implement MES aligned to ISA‑95 with electronic batch record (EBR); digitize execution and review; increase right‑first‑time and cut release cycle time.
  • Lab Informatics And LIMS Modernization: Implement Laboratory Information Management System (LIMS) and Electronic Laboratory Notebook (ELN) with instrument integration; improve data integrity, turnaround, and lifecycle control under Good Practice (GxP).
  • IT/OT Cybersecurity For GMP Manufacturing: Design network segmentation, identity, backup, and incident response for operational technology (OT) and cloud; implement NIST/ISA‑62443 controls; reduce ransomware risk and unplanned downtime.
  • GxP Cloud And CSV Governance: Establish compliant cloud strategy and vendor selection; create computer system validation (CSV) playbooks and DevOps controls; accelerate releases while sustaining audit‑ready GxP evidence.

Regulatory Affairs

  • Regulatory Strategy And Submission Roadmap: Set FDA/EMA strategy for ANDA 505(j) and biosimilar 351(k), interchangeability, indications extrapolation, reference product selection, timelines; de-risk approvals and accelerate time-to-market.
  • CMC Dossier Development And eCTD Publishing: Build Modules 2/3, Quality Overall Summary, control strategy, stability, comparability and process performance qualification; author and publish eCTD; reduce Refuse‑to‑Receive and deficiency letters.
  • Bioequivalence And Clinical Strategy For Approval: Design bioequivalence, pharmacokinetic/pharmacodynamic, immunogenicity, and switching studies; optimize protocols and statistics; secure agency alignment; enable ANDA and biosimilar interchangeability approvals faster.
  • Health Authority Engagement And Meeting Management: Plan and run pre‑submission, Type C, and biosimilar development meetings; craft briefing packages and responses; negotiate commitments; minimize review cycles, Refuse‑to‑Receive, and Complete Response Letters.
  • Post Approval Changes And Global Lifecycle Management: Manage supplements, EU variations, renewals, labeling and Risk Evaluation and Mitigation Strategy updates; harmonize global change control; accelerate approvals and maintain supply continuity.

Quality Management Systems

  • Pharmaceutical Quality System Design And Harmonization: Design and harmonize Pharmaceutical Quality System aligned to ICH Q10/Q8–Q12; standardize global procedures and metrics; reduce deviations, batch release cycle time, and compliance risk.
  • Deviation, CAPA, And Change Control Optimization: Redesign risk-based triage, root cause analysis, effectiveness checks, and change control; cut cycle time, recurrence, and closure backlog while improving right-first-time.
  • Data Integrity And GxP Controls: Implement ALCOA+ program, audit trails, access management, periodic reviews, and training; remediate FDA/EMA observations; strengthen data integrity and inspection outcomes across labs and manufacturing.
  • Supplier And CDMO Quality Oversight: Establish quality agreements, risk-based audits, metrics, and escalation; govern tech transfer, deviations, and change notifications; improve compliance, on-time-in-full, and continuity with external partners.
  • Inspection Readiness And Remediation: Run mock inspections, storyboards, and document sprints; coach SMEs; prioritize corrective actions; close 483s and observations; elevate FDA, EMA, and MHRA inspection readiness.

Pharmacovigilance & Safety

  • Pharmacovigilance Operating Model And QMS Design: Design PV operating model with QPPV oversight, PSMF, roles, SOPs, SLAs, KPIs; align to ICH E2 and EU GVP; improve inspection readiness and global compliance.
  • Signal Detection And Benefit-Risk Management: Build signal detection framework, quantitative disproportionality, literature monitoring, and governance; deliver validated PBRER/PSUR and benefit-risk assessments; improve patient safety, audit trail, and regulator confidence.
  • Case Management Process And Technology Optimization: Redesign intake, triage, MedDRA coding, causality; implement E2B(R3) gateways, EudraVigilance/FAERS integration, and Argus/Veeva; improve first-time-right, cycle time, and individual case safety report compliance.
  • Biosimilar Risk Management And Immunogenicity Surveillance: Design biosimilar risk management plans, PASS, registries, and traceability; plan switching studies and immunogenicity surveillance; meet EU GVP, FDA expectations and protect interchangeability claims.
  • Safety Agreement And Partner Governance: Set Safety Data Exchange Agreements (SDEAs), oversight forums, metrics, and audits for licensors, distributors, and CDMOs; ensure timely reporting, compliance, and seamless case exchange.

Connect with the right consultant

Umbrex rapidly connects you with independent professionals who combine top‑tier consulting experience at firms such as McKinsey, Bain, Boston Consulting Group with hands‑on roles.

Find a consultant in our Generics & Biosimilars Practice

Prefer email? Write to [email protected]